{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:11:40Z","timestamp":1790712700201,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["F31HL188955"],"award-info":[{"award-number":["F31HL188955"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001023","name":"AINSE Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001058","name":"Australian American Educational Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014711","name":"The University of Queensland Institute for Molecular Bioscience","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.nucmedbio.2026.109681","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:30:30Z","timestamp":1789774230000},"page":"109681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Automated clinical production, dosimetry estimates and preclinical safety considerations for clinical translation of a SOAT1-targeted PET imaging agent"],"prefix":"10.1016","volume":"162-163","author":[{"given":"Gina","family":"Kaup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford D.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade P.","family":"Winton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Raffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenelle","family":"Stauff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Kit","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen F.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Viglianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.H.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109681_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16288-4","article-title":"Structural insights into the inhibition mechanism of human sterol O-acyltransferase 1 by a competitive inhibitor","volume":"11","author":"Guan","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109681_bb0010","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0022-2275(20)32360-9","article-title":"Differential expression of ACAT1 and ACAT2 among cells within liver, intestine, kidney, and adrenal of nonhuman primates","volume":"41","author":"Lee","year":"2000","journal-title":"J Lipid Res"},{"issue":"24","key":"10.1016\/j.nucmedbio.2026.109681_bb0015","doi-asserted-by":"crossref","first-page":"16062","DOI":"10.1021\/acs.jmedchem.2c01265","article-title":"Targeting sterol O-acyltransferase\/acyl-CoA:cholesterol acyltransferase (ACAT): a perspective on small-molecule inhibitors and their therapeutic potential","volume":"65","author":"Bhattacharjee","year":"2022","journal-title":"J Med Chem"},{"issue":"22","key":"10.1016\/j.nucmedbio.2026.109681_bb0020","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1021\/jm00074a011","article-title":"Inhibitors of acyl-CoA:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agents","volume":"36","author":"Trivedi","year":"1993","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.nucmedbio.2026.109681_bb0025","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1021\/jm00037a016","article-title":"Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N\u2019-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity","volume":"37","author":"Trivedi","year":"1994","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.nucmedbio.2026.109681_bb0030","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1161\/01.CIR.0000147777.12010.EF","article-title":"Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions","volume":"110","author":"Tardif","year":"2004","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109681_bb0035","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMoa054699","article-title":"Effect of ACAT inhibition on the progression of coronary atherosclerosis","volume":"354","author":"Nissen","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.nucmedbio.2026.109681_bb0040","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jama.301.11.1131","article-title":"ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial","volume":"301","author":"Meuwese","year":"2009","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.nucmedbio.2026.109681_bb0045","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10637-020-00899-1","article-title":"A phase 1 study of Nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma","volume":"38","author":"Smith","year":"2020","journal-title":"Invest New Drugs"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109681_bb0050","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1210\/clinem\/dgaa381","article-title":"A phase 2, multicenter study of nevanimibe for the treatment of congenital adrenal hyperplasia","volume":"105","author":"El-Maouche","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nucmedbio.2026.109681_bb0055","author":"Millendo Therapeutics US, Inc"},{"issue":"2","key":"10.1016\/j.nucmedbio.2026.109681_bb0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.32604\/or.2023.027112","article-title":"A pan-cancer analysis identifies SOAT1 as an immunological and prognostic biomarker","volume":"31","author":"Huang","year":"2023","journal-title":"Oncol Res"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109681_bb0065","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/CIRCRESAHA.115.306247","article-title":"Imaging atherosclerosis","volume":"118","author":"Tarkin","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.nucmedbio.2026.109681_bb0070","series-title":"The vulnerable plaque: the real villain in acute coronary syndromes","author":"Liang","year":"2011"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109681_bb0075","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.nucmedbio.2026.109681_bb0080","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jss.2021.08.006","article-title":"Diagnostic impact of adrenal vein sampling in adrenal Cushing\u2019s syndrome","volume":"268","author":"Raje","year":"2021","journal-title":"J Surg Res"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109681_bb0090","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2967\/jnumed.122.263864","article-title":"Development of fluorinated NP-59: a revival of cholesterol use imaging with PET","volume":"63","author":"Brooks","year":"2022","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109681_bb0095","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1021\/acsmedchemlett.0c00127","article-title":"Synthesis and evaluation of 11C- and 18F-labeled SOAT1 inhibitors as macrophage foam cell imaging agents","volume":"11","author":"Hill","year":"2020","journal-title":"ACS Med Chem Lett"},{"issue":"14","key":"10.1016\/j.nucmedbio.2026.109681_bb0100","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/jlcr.1937","article-title":"Highlighting the versatility of the tracerlab synthesis modules. Part 2: fully automated production of [11C]-labeled radiopharmaceuticals using a Tracerlab FXC-Pro","volume":"54","author":"Shao","year":"2011","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2026.109681_bb0105","series-title":"USP 43-NF 38","article-title":"<823> Positron emission tomography drugs for compounding, investigational, and research uses radiopharmaceuticals for Pos- Itron emission tomography","year":"2020"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109681_bb0110","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109681_bb0115","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00004032-200309000-00006","article-title":"Physical models and dose factors for use in internal dose assessment","volume":"85","author":"Stabin","year":"2003","journal-title":"Health Phys"},{"key":"10.1016\/j.nucmedbio.2026.109681_bb0120","series-title":"Endocrine abstracts","article-title":"Characterization of adrenal-specific effects of ATR-101, a selective ACAT1 antagonist, in dogs","volume":"vol. 44","author":"Hunt","year":"2016"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109681_bb0125","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.apradiso.2008.08.015","article-title":"Studies into radiolytic decomposition of Fluorine-18 labeled radiopharmaceuticals for positron emission tomography","volume":"67","author":"Scott","year":"2009","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2026.109681_bb0130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41181-020-00110-z","article-title":"Use of 55 PET radiotracers under approval of a radioactive drug research committee (RDRC)","volume":"5","author":"Jackson","year":"2020","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109681_bb0140","first-page":"128","article-title":"Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans","volume":"48","author":"Scheinin","year":"2007","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109681_bb0145","first-page":"986","article-title":"FDA reconsiders rules around radiation dosimetry for first-in-human studies of investigational PET radiopharmaceuticals","volume":"66","author":"Dakanali","year":"2025","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109681_bb0150","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2967\/jnumed.125.270320","article-title":"Foregoing nonclinical dosimetry studies to support first-in-human studies of certain PET radiopharmaceuticals","volume":"66","author":"Plyku","year":"2025","journal-title":"J Nucl Med"},{"issue":"Suppl. 1","key":"10.1016\/j.nucmedbio.2026.109681_bb0155","article-title":"First-in-human PET imaging of cholesterol trafficking in overactive adrenal glands with [11C]nevanimibe","volume":"67","author":"Kaup","year":"2026","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109681_bb0160","series-title":"SNMMI: novel radiotracer effectively images overactive adrenal glands","author":"Carey","year":"2026"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:38:49Z","timestamp":1790710729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805126000806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":30,"alternative-id":["S0969805126000806"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109681","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Automated clinical production, dosimetry estimates and preclinical safety considerations for clinical translation of a SOAT1-targeted PET imaging agent","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109681"}}